Key Insights:
• Novartis AG acquires Avidity Biosciences for $12 billion (USD 72 per share) — the company’s largest deal in more than a decade, expanding its AI-powered RNA therapy portfolio.
• The acquisition strengthens Novartis’s neuromuscular and rare-disease pipeline with three late-stage RNA-based drugs forecast to generate multi-billion-dollar annual revenues.
• The move underscores a strategic shift toward AI-accelerated genetic medicine as Novartis prepares for post-2030 growth and next-generation therapeutic leadership.
AI and RNA Converge to Drive Next-Gen Drug Discovery
Novartis’s purchase of Avidity Biosciences marks a pivotal intersection between artificial intelligence and RNA-based drug design. Avidity’s proprietary Antibody Oligonucleotide Conjugate (AOC™) platform uses machine learning algorithms to optimize RNA molecules for precision targeting and delivery. By integrating this technology into its global R&D ecosystem, Novartis aims to dramatically shorten discovery timelines and improve success rates for complex rare-disease indications such as muscular dystrophy. This move signifies the evolution of big pharma into a data-driven biotech powerhouse, where AI algorithms guide molecular innovation from lab to clinic.
Strengthening the Rare-Disease and Neuromuscular Portfolio
The acquisition immediately positions Novartis as a leader in rare neuromuscular disorders, adding three late-stage RNA therapies that complement its established gene-therapy product Zolgensma. CEO Vas Narasimhan described the assets as “a complete strategic fit,” enabling Novartis to leverage existing sales and distribution channels for accelerated market penetration. Two of these programs are projected to reach multi-billion-dollar peak sales, with the third expected to generate up to $1 billion annually — collectively redefining the company’s growth trajectory before 2030.
AI-Enhanced Efficiency and Strategic Growth Outlook
Novartis expects the transaction to lift its compound annual revenue growth rate to 5–6 percent through 2029, even as it temporarily dilutes profit margins by 1–2 points. The deal reflects a deliberate strategy to strengthen the company’s portfolio ahead of patent expirations in the early 2030s. Avidity will spin off its cardiovascular programs into a separate entity, allowing Novartis to concentrate on high-value RNA and neuromuscular pipelines. Combined with recent acquisitions — Tourmaline Bio ($1.4 billion), Anthos Therapeutics ($3.1 billion), and Argo Biopharma ($5.2 billion licensing deal) — this transaction consolidates Novartis’s leadership in AI-augmented, data-driven precision medicine.
From Traditional Pharma to AI-Biotech Hybrid
The Avidity deal epitomizes Novartis’s transformation into a next-generation AI-biotech enterprise. The company is embedding digital intelligence into every phase of its operations — from molecular design and clinical trials to market analytics and patient insights. This hybrid model merges the computational speed of AI with the scientific depth of RNA biology, setting a new industry benchmark for agility and innovation. Analysts view the acquisition as more than a pipeline expansion; it’s a blueprint for how large pharma can pivot toward digital-first R&D ecosystems capable of sustainable growth in the era of smart therapeutics.
About Novartis AG
Novartis AG (SIX: NOVN; NYSE: NVS) is a leading global medicines company headquartered in Basel, Switzerland, committed to reimagining medicine through science, data, and digital technology. The company leverages AI-driven discovery and advanced manufacturing to deliver transformative therapies across oncology, cardiovascular, immunology, and rare-disease categories.
About Avidity Biosciences Inc.
Avidity Biosciences (NASDAQ: RNA) is a San Diego-based biotechnology innovator pioneering RNA therapeutics through its Antibody Oligonucleotide Conjugate (AOC™) platform. The company combines advanced data analytics, AI-guided molecular engineering, and targeted delivery systems to address rare genetic diseases with high unmet need.
By